Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Alzheimer's disease (AD) is the leading cause of dementia in older adults. Although AD
progression is characterized by stereotyped accumulation of proteinopathies, the affected …

Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …

Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised
questions about their preferential association with the hallmark pathologies of Alzheimer …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

For many years Alzheimer's disease (AD) was associated with the dementia stage of the
disease, the tail end of a pathophysiological process that lasts approximately two decades …

INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Glial fibrillary acidic protein (GFAP), a proxy of astrocyte reactivity, has been proposed as
biomarker of Alzheimer's disease. However, there is limited information about the correlation …